Wire · opportunities
FDA Approves Opus Genetics' Phentolamine Ophthalmic Solution 0.75% to Treat Presbyopia
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 October 2026 · Fusion42 review
The FDA approved Opus Genetics' phentolamine ophthalmic solution 0.75% for treating age-related presbyopia in adults, expanding its previous use for pharmacologically induced mydriasis. The approval follows successful phase 3 trials and will trigger a milestone payment from Viatris, who holds exclusive commercialization rights in the U.S.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You now have a new approved option to treat presbyopia in the U.S. with a drug that preserves distance vision. Ophthalmology founders can explore partnerships or development around pupil-diameter-modulating therapies.
◆ Coverage
1 source · 19 Oct 2026
◆ Related on Wire
◆ Topics